Literature DB >> 28254026

The fate of inhaled antibiotics after deposition in cystic fibrosis: How to get drug to the bug?

Aukje C Bos1, Kimberly M Passé2, Johan W Mouton3, Hettie M Janssens4, Harm A W M Tiddens5.   

Abstract

BACKGROUND: Chronic airway infections in patients with cystic fibrosis (CF) are most often treated with inhaled antibiotics of which deposition patterns have been extensively studied. However, the journey of aerosol particles does not end after deposition within the bronchial tree.
OBJECTIVES: To review how local conditions affect the clinical efficacy of antibiotic aerosol particles after deposition in the airways of patients with CF.
METHODS: Electronic databases were searched from inception to September 2015. Original studies describing the effect of CF sputum or bacterial factors on antibiotic efficacy and formulations to increase efficacy were included.
RESULTS: 35 articles were included which mostly described in vitro studies and mainly investigated aminoglycosides. After deposition, diffusion through the mucus layer was reduced for aminoglycosides, β-lactam antibiotics and fluoroquinolones. Within CF mucus, low oxygen tension adversely affected aminoglycosides, β-lactam antibiotics, and chloramphenicol; and molecules inactivated aminoglycosides but not β-lactam antibiotics. Finally, the alginate layer surrounding Pseudomonas aeruginosa was an important factor in the resistance against all antibiotics.
CONCLUSIONS: After deposition in the airways, the local efficacy of inhaled antibiotics can be reduced by molecules within CF mucus and the alginate layer surrounding P. aeruginosa.
Copyright © 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alginate; Cystic fibrosis; Inhaled antibiotics; Pseudomonas aeruginosa; Sputum binding

Mesh:

Substances:

Year:  2016        PMID: 28254026     DOI: 10.1016/j.jcf.2016.10.001

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  11 in total

1.  Assessing Human Airway Epithelial Progenitor Cells for Cystic Fibrosis Cell Therapy.

Authors:  Rhianna E Lee; Sean M Miller; Teresa M Mascenik; Catherine A Lewis; Hong Dang; Zachary H Boggs; Robert Tarran; Scott H Randell
Journal:  Am J Respir Cell Mol Biol       Date:  2020-09       Impact factor: 6.914

2.  N-Acetyl-Cysteine Increases Activity of Peanut-Shaped Gold Nanoparticles Against Biofilms Formed by Clinical Strains of Pseudomonas aeruginosa Isolated from Sputum of Cystic Fibrosis Patients.

Authors:  Ewelina Piktel; Urszula Wnorowska; Joanna Depciuch; Dawid Łysik; Mateusz Cieśluk; Krzysztof Fiedoruk; Joanna Mystkowska; Magdalena Parlińska-Wojtan; Paul A Janmey; Robert Bucki
Journal:  Infect Drug Resist       Date:  2022-03-05       Impact factor: 4.003

Review 3.  Biofilm antimicrobial susceptibility through an experimental evolutionary lens.

Authors:  Tom Coenye; Mona Bové; Thomas Bjarnsholt
Journal:  NPJ Biofilms Microbiomes       Date:  2022-10-18       Impact factor: 8.462

4.  Evolution of Antibiotic Resistance in Biofilm and Planktonic Pseudomonas aeruginosa Populations Exposed to Subinhibitory Levels of Ciprofloxacin.

Authors:  Marwa N Ahmed; Andreas Porse; Morten Otto Alexander Sommer; Niels Høiby; Oana Ciofu
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

5.  In vitro evaluation of drug delivery behavior for inhalable amorphous nanoparticle formulations in a human lung epithelial cell model.

Authors:  Jianting Chen; Maizbha U Ahmed; Chune Zhu; Shihui Yu; Weisan Pan; Tony Velkov; Jian Li; Qi Tony Zhou
Journal:  Int J Pharm       Date:  2021-01-21       Impact factor: 5.875

6.  Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.

Authors:  Hajira Bilal; Jessica R Tait; Yinzhi Lang; Jieqiang Zhou; Phillip J Bergen; Anton Y Peleg; Jürgen B Bulitta; Antonio Oliver; Roger L Nation; Cornelia B Landersdorfer
Journal:  Antimicrob Agents Chemother       Date:  2022-01-18       Impact factor: 5.938

7.  Targeted disruption of the extracellular polymeric network of Pseudomonas aeruginosa biofilms by alginate oligosaccharides.

Authors:  Lydia C Powell; Manon F Pritchard; Elaine L Ferguson; Kate A Powell; Shree U Patel; Phil D Rye; Stavroula-Melina Sakellakou; Niklaas J Buurma; Charles D Brilliant; Jack M Copping; Georgina E Menzies; Paul D Lewis; Katja E Hill; David W Thomas
Journal:  NPJ Biofilms Microbiomes       Date:  2018-06-29       Impact factor: 7.290

Review 8.  Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives.

Authors:  Giovanni Taccetti; Michela Francalanci; Giovanna Pizzamiglio; Barbara Messore; Vincenzo Carnovale; Giuseppe Cimino; Marco Cipolli
Journal:  Antibiotics (Basel)       Date:  2021-03-22

9.  Development and Preclinical Evaluation of New Inhaled Lipoglycopeptides for the Treatment of Persistent Pulmonary Methicillin-Resistant Staphylococcus aureus Infections.

Authors:  Adam J Plaunt; Sasha J Rose; Jeong Yeon Kang; Kuan-Ju Chen; Daniel LaSala; Ryan P Heckler; Arielle Dorfman; Barrett T Smith; Donald Chun; Veronica Viramontes; Antonio Macaluso; Zhili Li; Yuchen Zhou; Lilly Mark; Jessica Basso; Franziska G Leifer; Michel R Corboz; Richard W Chapman; David Cipolla; Walter R Perkins; Vladimir S Malinin; Donna M Konicek
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

10.  Alginate oligosaccharides enhance diffusion and activity of colistin in a mucin-rich environment.

Authors:  Joana Stokniene; Mathieu Varache; Philip D Rye; Katja E Hill; David W Thomas; Elaine L Ferguson
Journal:  Sci Rep       Date:  2022-03-23       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.